

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**


**THIS PAGE BLANK (USPTO)**

2417  
EP

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07C 307/02, A61K 31/225, C07D 209/20, C07C 331/10, C07D 295/08, 333/34, C07C 323/59</p>	A1	<p>(11) International Publication Number: WO 97/44314</p> <p>(43) International Publication Date: 27 November 1997 (27.11.97)</p>
<p>(21) International Application Number: PCT/US97/06725</p> <p>(22) International Filing Date: 21 April 1997 (21.04.97)</p> <p>(30) Priority Data: 60/017,882 17 May 1996 (17.05.96) US</p>	<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Helen, Tsenwhei [US/US]; 3625 Fox Hunt, Ann Arbor, MI 48105 (US). PICARD, Joseph, Armand [US/US]; 44809 Saltz Road, Canton, MI 48187 (US). ROARK, William, Howard [US/US]; 2810 Gladstone Avenue, Ann Arbor, MI 48104 (US). ROTH, Bruce, David [US/US]; 49255 Hunt Club Court, Plymouth, MI 48170 (US). SLISKOVIC, Drago, Robert [GB/US]; 3679 Hedgerow Drive, Saline, MI 48176 (US).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>	<p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: N-ACYL SULFAMIC ACID ESTERS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS</p>		
<p>(57) Abstract</p> <p>The instant invention is new compounds of formula (I), wherein R<sup>6</sup> is -CN, -(CH<sub>2</sub>)<sub>0-10</sub>-NR<sup>7</sup>R<sup>8</sup>, -O-(CH<sub>2</sub>)<sub>1-10</sub>-Z wherein Z is -NR<sup>9</sup>R<sup>10</sup>, OR<sup>1</sup>, or CO<sub>2</sub>R<sup>1</sup>, -OC(=O)R<sup>11</sup>, -SR<sup>11</sup>, -SCN, -S(CH<sub>2</sub>)<sub>1-10</sub>Z, -S(O)<sub>1-2</sub>R<sup>12</sup> wherein R<sup>12</sup> is hydroxy, alkoxy, alkyl, (CH<sub>2</sub>)<sub>1-10</sub>Z or NR<sup>7</sup>R<sup>8</sup>, -C(=O)XR<sup>11</sup>, -CH<sub>2</sub>-R<sup>13</sup> wherein R<sup>13</sup> is (CH<sub>2</sub>)<sub>0-5</sub>-Y-(CH<sub>2</sub>)<sub>0-5</sub>Z, or alkyl with from 1-3 double bonds, which alkyl is optionally substituted by one or more selected from -CN, NO<sub>2</sub>, halogen, OR<sup>1</sup>, NR<sup>9</sup>R<sup>10</sup>, and CO<sub>2</sub>R<sup>1</sup>; their use as cerebrovascular agents in diseases such as stroke, peripheral vascular disease, restenosis, and as agents for regulating plasma cholesterol concentrations, for treating hypercholesterolemia and atherosclerosis, and for lowering the serum or plasma level of Lp(a). A pharmaceutical composition is also claimed.</p> <div style="text-align: center;">  <p>(I)</p> </div>		

A0000417-01-CFP  
 USSN: 10/071,034 FILED: 2/08/02

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

## N-ACYL SULFAMIC ACID ESTERS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS

5

## BACKGROUND OF INVENTION

10 This invention relates to chemical compounds  
having pharmacological activity, to pharmaceutical  
compositions which include these compounds, and to  
pharmaceutical methods of treatment using the  
compounds. More particularly, this invention concerns  
15 certain N-acyl sulfamic acid esters with improved  
physical properties which inhibit the enzyme and acyl-  
coenzyme A:cholesterol acyltransferase (ACAT).

The compounds of the instant invention show  
increased chemical stability over those of United  
20 States Patent No. 5,245,068.

The compounds of the instant invention show  
improved physical properties (such as aqueous  
solubility, decreased lipophilicity, and improved  
dissolution rates) over those disclosed in United  
25 States Patent No. 5,491,172.

United States Patent Application 60/003,03 filed  
August 3, 1995, teaches other methods of using the  
compounds taught in Patent No. 5,491,172. Both of  
these are incorporated herein by reference.

30 In recent years the role which elevated blood  
plasma levels of cholesterol plays in pathological  
conditions in man has received much attention.  
Deposits of cholesterol in the vascular system have  
been indicated as causative of a variety of  
35 pathological conditions including coronary heart  
disease.

Initially, studies of this problem were directed  
toward finding therapeutic agents which would be  
effective in lowering total serum cholesterol levels.

-2-

It is now known that cholesterol is transported in the blood in the form of complex particles consisting of a core of cholesteryl esters plus triglycerides and a variety of types of protein which are recognized by specific receptors. For example, cholesterol is carried to the sites of deposit in blood vessels in the form of low density lipoprotein cholesterol (LDL cholesterol) and away from such sites of deposit by high density lipoprotein cholesterol (HDL cholesterol).

Following these discoveries, the search for therapeutic agents which control serum cholesterol turned to finding compounds which are more selective in their action; that is, agents which are effective in elevating the blood serum levels of HDL cholesterol and/or lowering the levels of LDL cholesterol. While such agents are effective in moderating the levels of serum cholesterol, they have little or no effect on controlling the initial absorption of dietary cholesterol in the body through the intestinal wall.


In intestinal mucosal cells, dietary cholesterol is absorbed as free cholesterol which must be esterified by the action of the enzyme, acyl-CoA:cholesterol acyltransferase (ACAT) before it can be packaged into the chylomicrons which are then released into the blood stream. Thus, therapeutic agents which effectively inhibit the action of ACAT prevent the intestinal absorption of dietary cholesterol into the blood stream or the reabsorption of cholesterol which has been previously released into the intestine through the body's own regulatory action.

The present invention relates to methods of using the novel compounds to lower plasma cholesterol and/or lipoprotein(a), Lp(a), and more particularly to methods and agents to lower their plasma concentrations to achieve therapeutic benefit.

-3-

## SUMMARY OF THE INVENTION

The present invention is compounds of the formula



or a pharmaceutically acceptable salt thereof wherein:

$R^1$  is hydrogen, alkyl, or alkoxy;

$R^2$  to  $R^5$  are alkyl, alkoxy, or unsubstituted or substituted phenyl;

15  $R^6$  is -CN-,

- $(CH_2)_{0-1}-NR^7R^8$ ,

-O- $(CH_2)_{1-10}-Z$  wherein Z is - $NR^9R^{10}$ ,  $OR^1$ , or  $CO_2R^1$ ,

-OC(=O) $R^{11}$ ,

20 - $SR^{11}$ ,

-SCN,

-S $(CH_2)_{1-10}Z$ ,

-S(O) $_{1-2}R^{12}$  wherein  $R^{12}$  is hydroxy, alkoxy, alkyl,  $(CH_2)_{1-10}Z$  or  $NR^7R^8$ ;

25 -C(=O) $XR^{11}$ ,

- $CH_2-R^{13}$  wherein  $R^{13}$  is  $(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$ , or

alkyl of from 1 to 20 carbons with from 1-3 double bonds, which alkyl is optionally substituted

by one or more moieties selected from -CN,

30  $NO_2$ , halogen,  $OR^1$ ,  $NR^9R^{10}$ , and  $CO_2R^1$ ;

wherein  $R^7$  and  $R^8$  are each independently selected from:

-hydrogen, at least one of  $R^7$  and  $R^8$  is other than hydrogen,

- $(CH_2)_{1-10}Z$  wherein Z is as defined above and  $R^9$

35 and  $R^{10}$  are each independently selected from

-4-

hydrogen, alkyl, and unsubstituted or substituted phenyl, or  $R^9$  and  $R^{10}$  are taken together with the nitrogen to which they are attached to form a ring selected from:

- 5
  - 10
  - 15
  - 20
  - 25
  - 30
- $(CH_2)_2-O-(CH_2)_2$ ,
  - $(CH_2)_2-S-(CH_2)_2$ ,
  - $(CH_2)_2-CR^{14}R^{15}-(CH_2)_{1-2}$ , and
  - $(CH_2)_2-NR^{16}-(CH_2)_2$ , wherein  $R^{14}$ ,  $R^{15}$ , and  $R^{16}$  are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl;
  - $C(=Q)XR^{11}$  wherein X is a bond or NH wherein Q is O or S,  $R^{11}$  is hydrogen, alkyl, unsubstituted or substituted phenyl,
  - $(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$  wherein Z is as defined above and Y is phenyl or a bond;
  - $C(=O)-CR^{17}R^{18}Z$ ;
  - $C(=O)NHC R^{17}R^{18}Z$  wherein  $R^{17}$  and  $R^{18}$  are each independently hydrogen, alkyl, phenyl, substituted phenyl, or the side chain of a naturally occurring amino acid;
  - $S(O)_{1-2}R^{19}$  wherein  $R^{19}$  is alkyl, unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring, or  $NR^9R^{10}$  or  $R^7$  and  $R^8$  are taken together with the nitrogen to which they are attached to form a ring:
  - $(CH_2)_2-O-(CH_2)_2$ ,
  - $(CH_2)_2-S-(CH_2)_2$ ,
  - $(CH_2)_2-CR^{14}R^{15}-(CH_2)_{1-2}$ ,
  - $(CH_2)_2-NR^{16}-(CH_2)_2$  wherein  $R^{14}$ ,  $R^{15}$ , and  $R^{16}$  are as above.

Preferred compounds of the invention are those of Formula I wherein:  
 $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;



-5-

$R^2$  to  $R^5$  are each alkyl of from 1 to 4 carbon atoms;  
 $R^6$  is  $-NR^7R^8$  wherein  $R^7$  and  $R^8$  are each independently  
selected from:

hydrogen, at least one of  $R^7$  and  $R^8$  is not  
hydrogen,

$-(CH_2)_{1-10}Z$ ,

$-C(=O)XR^{11}$ , or

$-S(O)_{1-2}R^{19}$ .

More preferred compounds are those of Formula I

wherein

$R^7$  is hydrogen and

$R^8$  is  $-C(=O)CR^{17}R^{18}Z$  wherein  $Z$  is  $NH_2$  where one of  $R^{17}$   
and  $R^{18}$  is the side chain of a naturally occurring  
amino acid and the other is hydrogen.

Other preferred compounds are those of Formula I  
wherein:

$R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;

$R^2$  to  $R^5$  are each alkyl of from 1 to 4 carbon atoms;

$R^6$  is  $NR^7R^8$  wherein  $R^7$  and  $R^8$  taken together with the  
nitrogen to which they are attached to form a ring:

$-(CH_2)_2-O-(CH_2)_2-$ ,

$-(CH_2)_2-S-(CH_2)_2-$ ,

$-(CH_2)_2-CR^{14}R^{15}-(CH_2)_2-$  wherein  $R^{14}$  and  $R^{15}$  are  
each independently selected from hydrogen,  
alkyl, or phenyl, or

$-(CH_2)_2-NR^{16}-(CH_2)_2-$  wherein  $R^{16}$  is hydrogen,  
alkyl, or phenyl.

Still other preferred compounds are those of  
Formula I wherein:

$R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;

$R^2$  to  $R^5$  are each alkyl of from 1 to 4;

$R^6$  is  $NR^7R^8$  wherein one of  $R^7$  and  $R^8$  is hydrogen and  
the other is  $S(O)_{1-2}R^{19}$ .

More preferred compounds are those of Formula I

wherein

$R^1$  is hydrogen or alkyl of from 1 to 4 carbons,

-6-

$R^2$  to  $R^5$  are alkyl of from 1 to 4 carbons, and  
 $R^6$  is  $-C(=O)XR^{11}$  or  $-CH_2R^{13}$ .

Still other preferred compounds are those of  
 Formula I wherein:

- 5  $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms;  
 $R^6$  is  $-O-(CH_2)_{1-10}Z$ ,  
 $-O-C(=O)R^{11}$ ,  
 $-SH$ ,  
 10  $-SCN$ ,  
 $-S(CH_2)_{1-10}Z$ , or  
 $-S(O)_{1-2}R^{12}$ .

Other preferred compounds are those of Formula I  
 wherein

- 15  $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms;  
 $R^6$  is  $O(CH_2)_{1-10}NR^9R^{10}$ .

Especially preferred are:

- (S) - [5-tert-Butoxycarbonylamino-5-(3,5-  
 20 diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-  
 acetyl]sulfamoyloxy}-phenylcarbamoyl)-pentyl]-carbamic  
 acid tert-butyl ester;  
 (S) - [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
 acid 4-(2,6-diamino-hexanoylamino)-2,6-diisopropyl-  
 25 phenyl ester dihydrochloride;  
 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
 4-(2-t-butoxycarbonylamino-acetylamino)-2,6-  
 diisopropyl-phenyl ester;  
 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
 30 4-(2-amino-acetylamino)-2,6-diisopropyl-phenyl ester;  
 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-  
 butyrylamino)-2,6-diisopropyl-phenyl ester;  
 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
 35 4-(2-amino-4-methylsulfanyl-butyrylamino)-  
 2,6-diisopropyl-phenyl ester trifluoroacetate;

-7-

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester;

5 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid;

----- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid -----  
4-[2-amino-3-(1H-indol-3-yl)-propionylamino]-2,6-diisopropyl-phenyl ester;

10 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(5-amino-pentanoylamino)-2,6-diisopropyl-phenyl ester  
trifluoroacetate(1:1) (salt);

(D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl  
15 ester trifluoroacetate(1:1) (salt);

(L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(2-amino-propionylamino)-2,6-diisopropyl-phenyl  
ester;

20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(2-amino-2-methyl-propionylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl  
ester;

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl  
ester hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester  
30 hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-thiocyanato-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-cyano-2,6-diisopropyl-phenyl ester;

- 8 -

- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-[(2-amino-acetyl-amino)-methyl]-2,6-diisopropyl-phenyl  
ester;
- 5 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-formyl-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester  
10 mono hydrochloride;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-(4-methyl-piperazin-1-ylmethyl)-  
phenyl ester, dihydrochloride;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
15 4-carbamoyl-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-hydroxymethyl-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-acetyl-amino-2,6-diisopropyl-phenyl ester;
- 20 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(2-hydroxy-ethyl-amino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-[bis-(2-hydroxy-ethyl)-amino]-2,6-diisopropyl-phenyl  
ester;
- 25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-  
phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester;
- 30 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-(3-phenyl-thioureido)-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-(thiophene-2-sulfonylamino)-phenyl  
ester;

-9-

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-(5-dimethylamino-naphthalene-1-sulfonylamino)-  
2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
5 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
2,6-diisopropyl-4-sulfamoyl-phenyl ester;

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl-  
acetyl)sulfamoyloxy]-phenyl)-hexanoic acid ethyl ester;  
10 and

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl-  
acetyl)sulfamoyloxy]-phenyl)-hexanoic acid.

The compounds of the invention are useful in  
15 treating cerebrovascular diseases such as stroke,  
peripheral vascular diseases, and restenosis. They are  
useful in lowering serum or plasma levels of Lp(a).  
They are agents for regulating plasma cholesterol  
concentrations. The compounds are useful in treating  
20 hypercholesteremia and atherosclerosis.

Pharmaceutical compositions containing one or more  
of the compounds are also part of this invention.

Novel intermediates are also part of the  
invention.

25

#### DETAILED DESCRIPTION

The compounds of the present invention provide a  
30 novel class of N-acyl sulfamic acid esters (or  
thioesters), N-acyl sulfonamides, and N-sulfonyl  
carbamic acid esters (or thioesters) which are ACAT  
inhibitors, rendering them useful in pharmaceutical  
treatments. The advantage of the instant invention is  
35 the improved physical properties which provide  
compounds suitable as pharmaceuticals.

-10-

In Formula I above, illustrative examples of straight or branched carbon chains having from 1 to 10 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, and n-octyl.

Alkoxy means straight or branched groups having from 1 to 6 carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.

The natural (essential) amino acids are: valine, leucine, isoleucine, threonine, methionine, phenylalanine, tryptophan, lysine, alanine, aginine, aspartic acid, cysteine, glutamic acid, glycine, histidine, proline, serine, tyrosine, asparagine, and glutamine.

Preferred natural amino acids are: valine, leucine, isoleucine, threonine, lysine, alanine, glycine, serine, asparagine, and glutamine.

Phenyl, naphthyl, and heteroaromatic rings are unsubstituted or substituted by from 1 to 5 substituents selected from alkyl of from 1 to 6 carbons, alkoxy, halogen, nitro, cyano, carboxylic acids and alkyl esters, amino, and hydroxyl.

Heteroaromatic rings are, for example, 2-, 3-, or 4-pyridinyl; 2-, 4-, or 5-pyrimidinyl; 2- or 3-thienyl; isoquinolines, quinolines, pyrroles, indoles, and thiazoles.

Preferred substituents are halogen, for example, fluoro and chloro, methoxy, and amino.

Pharmaceutically acceptable salts of the compounds of Formula I are also included as a part of the present invention.

The base salts may be generated from compounds of Formula I by reaction of the latter with one equivalent of a suitable nontoxic, pharmaceutically acceptable base followed by evaporation of the solvent employed for the reaction and recrystallization of the salt, if

-11-

required. The compounds of Formula I may be recovered from the base salt by reaction of the salt with an aqueous solution of a suitable acid such as hydrobromic, hydrochloric, or acetic acid.

5           Suitable bases for forming base salts of the compounds of this invention include amines such as triethylamine or dibutylamine, or alkali metal bases and alkaline earth metal bases. Preferred alkali metal hydroxides and alkaline earth metal hydroxides as salt  
10           formers are the hydroxides of lithium, sodium, potassium, magnesium, or calcium. The class of bases suitable for the formation of nontoxic, pharmaceutically acceptable salts is well known to practitioners of the pharmaceutical formulation arts.  
15           See, for example, Berge SN, et al, J. Pharm. Sci., 1977;66:1-19.

          Suitable acids for forming acid salts of the compounds of this invention containing a basic group include, but are not necessarily limited to acetic,  
20           benzoic, benzenesulfonic, tartaric, hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic, methanesulfonic, pamoic, salicylic, stearic, succinic, sulfuric, and tartaric acids. The acid addition salts are formed by  
25           procedures well known in the art.

          The compounds of the present invention may also exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compound. The present invention contemplates all stereoisomeric  
30           forms of the compounds as well as mixtures thereof, including racemic mixtures.

          Further, the compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water,  
35           ethanol and the like. In general, the solvated forms

-12-

are considered equivalent to the unsolvated forms for the purposes of this invention.

The ability of the compounds of the present invention to lower Lp(a) is evaluated in the following procedure. Nine male cynomolgus monkeys (*Macaca fascicularis*, 4-5 kg) are maintained on a standard monkey chow diet (containing less than 5% fat and only trace amounts of cholesterol). The diet is available daily from 9 AM until 2 PM. These animals transport approximately equal amounts of cholesterol in HDL (47%) and LDL (51%) and have low triglycerides compared to humans (approximately 50 mg/dL). Five weekly blood samples are taken from anesthetized, restrained animals, and then the animals were dosed with the desired compound daily before meals (for 3 weeks at 30 mg/kg) by incorporating it into oatmeal cream pies (Little Debbie Snack Cakes, McKee Foods, Collegedale, Tennessee). Tang breakfast beverage crystals (Kraft General Foods, Inc., White Plains, New York), and additional cream filling is also added to individual servings. Most animals consume the drug-containing treat immediately since they are without food during the night. They are not given their daily meal until they have consumed the treat. Mean plasma cholesterol (top line) and Lp(a) (bottom line) values are calculated (all values in mg/dL).

The average baseline values for cholesterol and Lp(a) are calculated. Using these values, the percentage decreases for cholesterol and Lp(a) are known. It is important to note that every animal demonstrates a decrease in cholesterol and Lp(a). The decrease in total cholesterol is due primarily to a decrease in LDL-cholesterol.

The compounds of the present invention are thus useful in pharmaceutical formulations for the treatment of stroke, peripheral vascular disease, and restenosis.



-13-

In therapeutic use as agents for treating stroke, peripheral vascular disease, and restenosis, the compounds of Formula I or pharmaceutically acceptable salts thereof are administered to the patient at dosage levels of from 250 to 3000 mg per day. For a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 5 to 40 mg/kg of body weight per day. The specific dosages employed, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art.

As shown by the data presented below in Table 1, the compounds of the present invention are inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase (ACAT), and are thus effective in inhibiting the esterification and transport of cholesterol across the intestinal cell wall. The compounds of the present invention are thus useful in pharmaceutical formulations for the treatment of hypercholesterolemia or atherosclerosis.

The ability of representative compounds of the present invention to inhibit ACAT was measured using an in vitro test more fully described in Field FJ, Salone RG, Biochemica et Biophysica 1982;712:557-570. The test assesses the ability of a test compound to inhibit the acylation of cholesterol by oleic acid by measuring the amount of radiolabeled cholesterol oleate formed from radiolabeled oleic acid in a tissue preparation containing rat liver microsomes.

The data appear in Table 1 where they are expressed in  $IC_{50}$  values; i.e., the concentration of test compound required to inhibit the activity of the enzyme by 50%.

-14-

TABLE 1. In Vitro Biological Data

	Example	LAI ( $\mu\text{M}$ )
	1	23
	2	>50
5	3	18
	4	48
	6	750
	7	49
	8	>50
10	9	24
	10	--
	11	>50
	12	>50
	13	>50
15	14	>50
	15	>50
	16	>50
	17	29
	18	>50
20	19	>50
	20	43.2
	21	44.6
	22	22.8
	23	50
25	24	43.8
	25	38.5
	26	30
	27	43
	28	43.8
30	29	33
	30	20.3
	31	37.4
	32	31.1
	33	10.6
35	34	45
	35	50
	36	19
	37	>50

-15-

In one in vivo screen designated APCC, male Sprague-Dawley rats (200 to 225 g) were randomly divided into treatment groups and dosed at 4 PM with either vehicle (CMC/Tween) or suspensions of compounds in vehicle. The normal chow diet was then replaced with a high fat, high cholesterol diet (designated PCC) containing 0.5% cholic acid. The rats consumed this diet ad libitum during the night and were sacrificed at 8 AM to obtain blood samples for cholesterol analysis using standard procedures. Statistical differences between mean cholesterol values for the same vehicle were determined using analysis of variance followed by Fisher's least significant test. The results of this trial for representative compounds of the present invention appear in Table 2.

TABLE 2

Compound of Example	APCC % Change in Plasma TC (dose in mg/kg)
20	1 +7 (1)
	2 -60 (10)
	3 -40 (30)
	4 -65 (10)
	6 -72 (10)
25	7 -30 (30)
	8 -15 (10)
	9 -25 (10)
	10 -15 (10)
	11 -19 (10)
30	12 -74 (10)
	13 -8 (10)
	14 -11 (10)
	15 -26 (10)
	16 -47 (10)
35	17 -46 (10)
	18 -38 (10)
	19 -16 (10)

-16-

TABLE 2

	Compound of Example	APCC % Change in Plasma TC (dose in mg/kg)
5	20	-44 (10)
	21	-35 (10)
	22	-18 (10)
	23	5 (10)
	24	-5 (10)
10	25	-54 (10)
	26	-44 (10)
	27	---
	28	-48 (10)
	29	-3 (10)
15	30	-30 (10)
	31	-21 (10)
	32	-60 (10)
	33	-61 (10)
	34	-13 (10)
20	35	---
	36	-17 (10)
	37	-47 (10)

In therapeutic use as agents for treating  
 hypercholesterolemia or atherosclerosis, the compounds  
 of Formula I or pharmaceutically acceptable salts  
 thereof are administered to the patient at dosage  
 levels of from 250 to 3000 mg per day. For a normal  
 human adult of approximately 70 kg of body weight, this  
 translates into a dosage of from 5 to 40 mg/kg of body  
 weight per day. The specific dosages employed,  
 however, may be varied depending upon the requirements  
 of the patient, the severity of the condition being  
 treated, and the activity of the compound being  
 employed. The determination of optimum dosages for a  
 particular situation is within the skill of the art.

For preparing the pharmaceutical compositions from  
 the compounds of this invention, inert,

-17-

pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets.

5           A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

10           In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the  
15           shape and size desired.

          Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers are magnesium  
20           dicarbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

          The term "preparation" is intended to include the formulation of the active compound with encapsulating  
25           material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner cachets or transdermal systems are also included.

30           Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

          Liquid form preparations include solutions, suspensions, or emulsions suitable for oral  
35           administration. Aqueous solutions for oral administration can be prepared by dissolving the active

-18-

compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in  
5 water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethylcellulose, and other suspending agents known to the pharmaceutical formulation art.

Preferably, the pharmaceutical preparation is in  
10 unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation containing discrete quantities of the preparation, for example, packeted  
15 tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of these packaged forms.

20

## GENERAL SYNTHETIC METHODS

Some intermediates for compounds of the present invention are readily obtainable using the methods  
25 set forth in Lee, et al., United States Patent No. 5,491,172. Thus, as shown in Scheme 1, a 4-nitrophenol (I) is reacted with N-chlorosulfonyl isocyanate at elevated temperatures, and quenched with water to give the 4-nitro sulfamate (II). This is then coupled  
30 with the phenyl acetic acid analog (III) using standard coupling techniques (e.g., DCC, CDI, acid chloride, and mixed anhydride) to give the compound (IV). Simple reduction of the nitro group (Raney Nickel/hydrogen) gives the amino compound (V) which can be  
35 functionalized to give the compounds of the present invention. For example, alkylating with an activated

-19-

alkyl group  $X-(CH_2)_nNR^9R^{10}$  (where X is halo, triflate, or other similar leaving groups known to those skilled in the art, and n,  $R^7$ , and  $R^8$  have the meanings defined in the scope of Formula I) gives a compound (VI) of the present invention. Similarly, reacting the amino compound (V) with an activated acyl group  $L-C(O)R^{11}$  (where L is a group that activates carboxylic acid coupling reactions such as halo, imidazole, mixed anhydride, and  $R^{11}$  has the meaning defined in the scope of Formula I) gives an amide compound (VII) of the present invention. The amino compound (V) can also be reacted with activated sulfonyl compounds  $(LS(O)_2R^{12})$  wherein  $R^{12}$  has the meaning defined in the scope of Formula I) to give sulfonamides (VIII) and with di-alkyl compounds  $(X(CH_2)_2Z(CH_2)_2X)$  wherein Z is O, S, NR, or  $CRR^1$  and X is halo, triflate, or other similar leaving groups known to those skilled in the art) to give the cyclic compounds (IX).

Synthesis of the corresponding oxygen analogs is shown in Scheme 2. A protected dihydroquinone (X) (where the protecting group can be any of the groups known to those skilled in the art, such as silyl ethers, benzyl ethers, alkyl ethers, and acyl groups) is treated with N-chlorosulfonyl isocyanate at elevated temperatures, and quenched with water to give the sulfamate (XI). This is then coupled with the phenyl acetic acid analog (III) using standard coupling techniques (e.g., DCC, CDI, acid chloride, or mixed anhydride,) to give the compound (XII). Deprotection of the hydroxyl group gives the hydroxy compound (XIII) which can be functionalized to give the compounds of the present invention. For example, alkylating with an activated alkyl group  $X-(CH_2)_nNR^9R^{10}$  (where X, n,  $R^9$ , and  $R^{10}$  have the meanings defined in the scope of this patent) gives an ether compound (XIV) of the present invention. Similarly, reacting the hydroxy compound

-20-


(XIII) with an activated acyl group  $L-C(O)R^{11}$  (where L is a group that activates carboxylic acid coupling reactions such as halo, imidazole, or mixed anhydride) gives an ester compound (XV) of the present invention.

- 5           One method to obtain the sulfur analogs of the present invention is shown in Scheme 3. A 4-thiocyanato phenol (XVI) is reacted with N-chlorosulfonyl isocyanate at elevated temperatures, and quenched with water to give the sulfamate (XVII).
- 10       This is then coupled with the phenyl acetic acid analog (III) using standard coupling techniques (e.g., DCC, CDI, acid chloride, or mixed anhydride) to give the thiocyanato compound of the present invention (XVIII). Hydrolysis of the thiocyanato group gives the thiol
- 15       (XIX) which can be functionalized to give the compounds of the present invention. For example, alkylating with an activated alkyl group  $X-(CH_2)_nNR^9R^{10}$  (where X is halo, triflate, or other similar leaving groups known to those skilled in the art, and n,  $R^9$ , and  $R^{10}$  have
- 20       the meanings defined in the scope of this patent) gives a thioether compound (XX) of the present invention. Oxidation of the thioether (XX) gives the sulfoxide (XXI, m = 1) or sulfone (XXI, m = 2). The thiocyanato compound (XVIII) can also be oxidized to give the
- 25       sulfonic acid compound (XXII) which can be further functionalized by coupling with an activated alkyl group (X alkyl) to give the sulfonate ester (XXIII) or an amine ( $HNR^9R^{10}$ ) to give a sulfonamide (VXXIV).




- 21 -


Scheme 1



Scheme 2



Scheme 3



-24-

Synthesis of 2,6-bis(1-methylethyl)-4-nitrophenyl sulfamate

N-Chlorosulfonyl isocyanate (7.2 mL, 82.6 mmol) was added slowly to a warm solution of 2,6-bis(1-methylethyl)-4-nitrophenol (17.57 g, 78.7 mmol) in 400 mL toluene. The resulting solution was heated to reflux for 6 hours and then cooled to room temperature and concentrated to give a brown oil. Quenched with 200 g ice and extracted with 4 x 500 mL dichloromethane. The organic solution was dried over MgSO<sub>4</sub>, filtered, and concentrated to give a tan solid. Recrystallization from dichloromethane gave 14.18 g (60%) of the title compound as an off-white solid; mp 163-167°C.

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester

Oxalyl chloride (0.52 mL, 5.9 mmol) was added dropwise to a solution of 2,4,6-tris(1-methylethyl)-phenyl acetic acid in 150 mL toluene with four drops N,N-dimethylformamide added as a catalyst. The resulting solution was stirred for 4 hours at room temperature and concentrated in vacuo. The residue was redissolved in 200 mL dichloromethane with 2,6-bis(1-methylethyl)-4-nitrophenyl sulfamate (1.50 g, 4.9 mmol) and excess (3 mL) triethylamine and stirred for 16 hours. The reaction was washed with 1 M HCl, dried over MgSO<sub>4</sub>, filtered, and concentrated to give an oily solid. Recrystallization from hexanes gave 2.37 g (87%) of the title compound as a white solid; mp 85-89°C.

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester

22.0 g of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester

-25-

and 6 g of Raney nickel were mixed in 110 mL tetrahydrofuran under 50 psi of hydrogen. After 21 hours, the reaction was filtered and concentrated to give an orange oil which was dissolved in ethyl acetate, filtered through a pad of silica, and concentrated to give an oily solid. Recrystallization from 5% diethyl ether/hexanes gave 18.60 g (89%) of the title compound as a cream colored solid; mp 153-155°C.

10 Synthesis of 2,6-Bis(1-methylethyl)-4-cyanophenyl sulfamate

Step (a) 2,6-Bis(1-methylethyl)-4-(N-(1-methylethyl)carboxamide)phenol

4-Cyanophenol (40.0 g, 336 mmol) was added in portions to a mixture of isopropanol (103 mL, 1.34 mol) and 80% sulfuric acid (300 mL) at 70°C. Heated for 20 hours then cooled to room temperature and quenched with ice. The resulting suspension was extracted with ethyl acetate. The ethyl acetate layer was dried over magnesium sulfate, filtered, and concentrated to give a green oil. Chromatography on silica gel (30% ethyl acetate/hexanes) gave 46.0 g of 2,6-bis(1-methylethyl)-4-(N-(1-methylethyl)carboxamide)phenol as a white solid; mp 165-167°C.

25

Step (b) 2,6-Bis(1-methylethyl)-4-cyanophenyl sulfamate

N-Chlorosulfonyl isocyanate (3.5 mL, 39.9 mmol) was added slowly to a warm solution of 2,6-bis(1-methylethyl)-4-(N-(1-methylethyl)carboxamide)phenol (5.0 g, 19.0 mmol) in 300 mL toluene. The resulting solution was heated to reflux for 6 hours and then cooled to room temperature and concentrated to give a brown oil. Quenched with 200 g ice and extracted with ethyl acetate. The organic solution was dried over magnesium sulfate, filtered, and concentrated to give a

-26-

tan solid. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 1.20 g of the title compound as an off-white solid.

5     Synthesis of 2,6-Bis(1-methylethyl)-4-formylphenyl sulfamate

          N-Chlorosulfonyl isocyanate (21.6 mL, 248 mmol) was added slowly to a warm solution of 3,5-diisopropyl-4-hydroxy-benzaldehyde (24.4 g, 118 mmol) in 500 mL  
10     toluene. The resulting solution was heated to reflux for 4 hours and then cooled to room temperature and concentrated to give a brown oil. Quenched with 200 g ice and extracted with ethyl acetate. The organic solution was dried over magnesium sulfate, filtered,  
15     and concentrated to give a tan solid. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 11.15 g of the title compound as an off-white solid.

20     Synthesis of 3,5-Diisopropyl-4-([[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy]-benzoic acid methyl ester

Step (a) 3,5-Bis(1-methylethyl)-4-

(sulfamoyloxy)benzoic acid methyl ester

          N-Chlorosulfonyl isocyanate (2.12 mL, 24.3 mmol) was added slowly to a warm solution of 3,5-diisopropyl-4-hydroxy-benzoic acid methyl ester (5.47 g, 23.1 mmol)  
25     in 300 mL toluene. The resulting solution was heated to reflux for 6 hours and then cooled to room temperature and concentrated to give a brown oil. Quenched with 200 g ice and extracted with ethyl  
30     acetate. The organic solution was dried over magnesium sulfate, filtered, and concentrated to give a tan solid. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 3.58 g of the title compound as an off-white solid.

-27-

Step (b) 3,5-Diisopropyl-4-([(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-benzoic acid methyl ester

Oxalyl chloride (1.12 mL, 12.8 mmol) was added dropwise to a solution of 2,4,6-triisopropylphenyl acetic acid (3.05 g, 11.6 mmol) in 150 mL toluene with 4 drops of N,N-dimethylformamide as a catalyst. The resulting solution was stirred overnight and then concentrated in vacuo. The residue was re-dissolved in 150 mL dichloromethane. 3,5-Bis(1-methylethyl)-4-(sulfamoyloxy)benzoic acid methyl ester (3.48 g, 11.6 mmol) and triethylamine (4.0 mL) were added and the resulting mixture was stirred for 2 hours. Washed with 1 M HCl, dried the organic layer over magnesium sulfate, filtered, and concentrated to give an off-white foam. Recrystallized (hexanes) to give 5.21 g of the title compound as a white solid; mp 144-146°C.

Synthesis of 6-(3,5-Diisopropyl-4-sulfamoyloxy-phenyl)-hexanoic acid ethyl ester

Step (a) 6-(4-Hydroxy-3,5-diisopropyl-phenyl)-6-oxo-hexanoic acid ethyl ester

Monomethyl adipate (61 g, 350 mmol) was treated with excess oxalyl chloride in tetrahydrofuran. The mixture was concentrated, and the resulting acid chloride was mixed with 2,6-Diisopropyl phenol (57 g, 350 mmol) at 0°C. Aluminum chloride (93 g, 700 mmol) and a catalytic amount of 1,2-dichloroethane were added in portions, and the mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with 1 M HCl and extracted with ethyl acetate. Concentrated in vacuo and chromatographed the residue to give the expected product.

-28-

Step (b) 6-(4-Hydroxy-3,5-diisopropyl-phenyl)-hexanoic acid ethyl ester

Boron trifluoride diethyl etherate (4.8 mL, 39 mmol) was added to a mixture of 6-(4-hydroxy-3,5-diisopropyl-phenyl)-6-oxo-hexanoic acid ethyl ester (13.19 g, 39.4 mmol) and ethanedithiol (3.5 mL, 39.3 mmol) in dichloromethane (100 mL), and the resulting deep red mixture was stirred overnight at room temperature. An additional amount of boron trifluoride diethyl etherate (1.2 mL, 10 mmol) was added, and the reaction mixture was stirred an additional 4 hours at room temperature. The reaction mixture was washed with saturated aqueous sodium bicarbonate solution, and the organic solution was dried over magnesium sulfate, filtered, and concentrated to an orange oil. The oil was chromatographed on silica gel (70-230 mesh) using 19:1, then 9:1, then 83:17 hexanes/ethyl acetate, v/v, as eluant. A mixture of this dithioketal (3.65 g, 8.9 mmol), Raney nickel (41 g of a slurry in water), and ethanol (250 mL) is heated to 50°C for 2.5 hours under nitrogen. No starting material remained by tlc. The ethanol was decanted from the nickel and the nickel washed and decanted twice with ethanol. The combined ethanol solutions were passed through celite, the ethanol evaporated, and the residue chromatographed on silica gel (70 230 mesh) using 4:1, hexanes/ethyl acetate as eluant. The product was obtained as a yellow oil in two portions, 2.95 g.

CI Mass Spectrum:  $[M + H^+]^+ = 320$ .

Step (c) 6-(3,5-Diisopropyl-4-sulfamoyloxy-phenyl)-hexanoic acid ethyl ester

Sodium hydride (0.257 g, 6.4 mmol) was added to 6-(4-hydroxy-3,5-diisopropyl-phenyl)-hexanoic acid ethyl ester (1.46 g, 5.0 mmol) in dimethylformamide



-29-

(20 mL) at 0°C over about 3 minutes. The cooling bath was removed, and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was cooled to zero degrees and sulfamoyl chloride (1.18 g, 10.3 mmol) was added over ~3 minutes. The reaction mixture was stirred 1.5 hours at zero degrees and was quenched by adding saturated aqueous sodium bicarbonate solution. The mixture is diluted with diethyl ether (300 mL) and water (100 mL). The organic layer is washed with water (3 x 100 mL), brine, dried over magnesium sulfate, filtered, and concentrated to an oil. The oil is chromatographed on silica gel using 4:1 hexanes/ethyl acetate as eluant. The title compound is obtained as a light yellow oil, 1.29 g. CI Mass Spectrum:  $[M + H^+]^+ = 400$ .

## EXAMPLE 1

Synthesis of (S)-[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamoyloxy]-phenylcarbamoyl]-pentyl]-carbamic acid tert-butyl ester

N,N-Dicyclohexylcarbodiimide (0.63 g, 3.0 mmol) was added to a solution of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester (1.5 g, 2.9 mmol) and bis-N,N'-(t-butoxycarbonyl)-(S)-lysine (1.1 g, 2.9 mmol) in 100 mL of dichloromethane at -15°C under an atmosphere of nitrogen. The resulting mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction was filtered, concentrated, and chromatographed on silica gel to give an oily solid. Recrystallization from 5% diethyl ether/hexanes gave 1.61 g (66%) of the title compound as a white solid; mp 167-171°C.

35

-30-

## EXAMPLE 2

Synthesis of (S)-[[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2,6-diamino-hexanoylamino)-2,6-diisopropyl-phenyl ester dihydrochloride

- 5 HCl (g) was bubbled through a solution of (S)-[5-tert-butoxycarbonylamino-5-(3,5-diisopropyl-4-  
{[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester  
(1.08 g, 1.3 mmol) in 150 mL methanol for 30 minutes.  
10 The reaction was concentrated, and the resulting foam was triturated with 5% dichloromethane/hexanes to give 0.88 g (96%) of the title compound as a tan solid; mp 172-179°C.

## EXAMPLE 3

- 15 Synthesis of [(3,5-Diisopropyl-4-{[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenylcarbamoyl)-methyl]-carbamic acid tert-butyl ester

- When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(t-butoxycarbonyl)-glycine, the title compound is  
20 obtained; mp 177-188°C.

## EXAMPLE 4

- 25 Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetyl-amino)-2,6-diisopropyl-phenyl ester

- When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with  
30 N-(9-fluorenylmethoxycarbonyl)-glycine, and the crude product is stirred in 20% piperidine/N,N-dimethyl-formamide for 0.5 hours and purified by chromatography, the title compound is obtained.

-31-

## EXAMPLE 5

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester

5           When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(t-butoxycarbonyl)-methionine, the title compound is obtained.

## EXAMPLE 6

10           Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate

15           (2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butyrylamino)-2,6-diisopropyl-phenyl ester (0.2 g, 0.3 mmol) was dissolved in 30 mL 50% trifluoroacetic acid/dichloromethane and stirred for 15 minutes. The  
20           title compound was isolated as an off-white solid.

## EXAMPLE 7

25           Synthesis of 3-[3-(3,5-Diisopropyl-4-{[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenyl)-ureido]-propionic acid ethyl ester

          Ethyl 3-isocyanatopropionate (0.29 g, 2.0 mmol) was added to a solution of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester (1.0 g, 1.9 mmol) in 50 mL dichloromethane  
30           under a dry air atmosphere. Stirred for 6 hours, concentrated in vacuo, and triturated the residue with 5% ethyl acetate in hexanes to give 1.04 g of the title compound as an off-white solid, mp 182-185°C.

-32-

## EXAMPLE 8

Synthesis of 3-[3-(3,5-Diisopropyl-4-[[2,4,6-triisopropyl-phenyl]-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid

5           3-[3-(3,5-Diisopropyl-4-[[2,4,6-triisopropyl-phenyl]-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester (0.54 g, 0.84 mmol) was suspended in 50 mL of 70% ethanol and 1.7 mL of 1M NaOH was added. The resulting mixture was stirred overnight, washed  
10 with diethyl ether, acidified with concentrated HCl, and extracted with dichloromethane. The organics were dried over magnesium sulfate, filtered, and concentrated to leave an oily solid which was triturated with 50% ethyl acetate in hexanes to give  
15 the title compound as a white solid, mp 179-181°C.

## EXAMPLE 9

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionylaminol-2,6-diisopropyl-phenyl ester

20           When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(9-fluorenylmethoxycarbonyl)-tryptophan, and the crude product is stirred in 20% piperidine/N,N-dimethylformamide for 0.5 hours and purified by  
25 chromatography, the title compound is obtained.

## EXAMPLE 10

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-amino-pentanoylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1) (salt)

30           When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(t-butoxycarbonyl)-5-aminopentanoic acid, and the  
35 t-butoxycarbonyl protecting group is removed by stirring for 15 minutes in a 50% trifluoroacetic acid

-33-

solution in dichloromethane, the title compound is obtained.

## EXAMPLE 11

5     Synthesis of (D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-  
      sulfamic acid 4-(2-amino-propionylamino)-2,6-  
      diisopropyl-phenyl ester trifluoroacetate(1:1)(salt)

      When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(t-butoxycarbonyl)-(D)-alanine, and the t-butoxycarbonyl protecting group is removed by stirring for 15 minutes in a 50% trifluoroacetic acid solution in dichloromethane, the title compound is obtained.

## EXAMPLE 12

15     Synthesis of (L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-  
      sulfamic acid 4-(2-amino-propionylamino)-2,6-  
      diisopropyl-phenyl ester

      When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(9-fluorenylmethoxycarbonyl)-(L)-alanine, and the crude product is stirred in 20% piperidine/N,N-dimethylformamide for 0.5 hours and purified by chromatography, the title compound is obtained.

## EXAMPLE 13

25     Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
      sulfamic acid 4-(2-amino-2-methyl-propionylamino)-2,6-  
      diisopropyl-phenyl ester

30     When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(9-fluorenylmethoxycarbonyl)-( $\alpha$ -methyl)alanine, and the crude product is stirred in 20% piperidine/N,N-dimethylformamide for 0.5 hours and purified by chromatography, the title compound is obtained.

35

-34-

## EXAMPLE 14

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-  
diisopropyl-phenyl ester

5      Step (a) 2,6-Bis(1-methylethyl)-1,4-dihydroquinone

A solution of potassium persulfate (30.33 g, 112 mmol) in 250 mL water was added dropwise over 1 hour to a solution of 2,6-bis(1-methylethyl)phenol (20.0 g, 112 mmol) in 250 mL 10% aqueous sodium  
10      hydroxide at 0°C. The resulting dark mixture was warmed to room temperature and stirred overnight. Neutralized to pH 7.0 with concentrated HCl and washed with diethyl ether. The aqueous layer was acidified with additional concentrated HCl and heated on a steam  
15      bath for 0.5 hour. Cooled to room temperature and extracted with diethyl ether. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give 10.5 g of 2,6-bis(1-methylethyl)-1,4-dihydroquinone as a dark oil which solidified upon  
20      standing.

Step (b) 4-(tert-butyl-dimethyl-silanyloxy)-2,6-  
diisopropylphenol

2,6-Bis(1-methylethyl)-1,4-dihydroquinone  
25      (21.32 g, 109 mmol) and tert-butyl-dimethyl-silyl chloride (18.2 g, 121 mmol) were mixed in 300 mL dichloromethane at room temperature. Triethylamine (18.4 mL, 133 mmol) was added, and the resulting mixture was stirred for 3 days. The reaction was  
30      washed with 1M HCl, and the organic layer was dried over magnesium sulfate, filtered, and concentrated to give 20.24 g of 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropyl-phenol as an orange oil.

-35-

Step (c) 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropylphenyl sulfamate

N-Chlorosulfonyl isocyanate (3.43 mL, 39.4 mmol) was added to a warm solution of 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropylphenol (11.59 g, 37.6 mmol) in 400 mL toluene. The resulting solution was heated to reflux for 6 hours and then cooled to room temperature and stirred overnight. The reaction was concentrated in vacuo, and the residue was quenched with ice water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give an orange oil. Chromatography on silica gel gave 6.06 g of 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropylphenyl sulfamate as an orange oil.

Step (d) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropyl-phenyl ester

Oxalyl chloride (2.45 mL, 28 mmol) was added dropwise to a solution of 2,4,6-triisopropylphenyl acetic acid (5.66 g, 21.6 mmol) in 150 mL toluene with 4 drops of N,N-dimethylformamide as a catalyst. The resulting solution was stirred for 6 hours and then concentrated in vacuo. The residue was redissolved in 150 mL dichloromethane. 4-(Tert-butyl-dimethyl-silanyloxy)-2,6-diisopropylphenyl sulfamate (8.36 g, 21.6 mmol) and triethylamine (7.5 mL, 54 mmol) were added, and the resulting mixture was stirred overnight. Washed with 1M HCl, dried the organic layer over magnesium sulfate, filtered, and concentrated to give 9.86 g of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropyl-phenyl ester.

-36-

Step (e) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6 diisopropyl-phenyl ester

A solution of 15 mL concentrated HF in 150 mL acetonitrile was added dropwise to a solution of  
5 [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(tert-butyl-dimethyl-silanyloxy)-2,6-diisopropyl-phenyl ester (9.71 g, 15.4 mmol) in 400 mL acetonitrile at room temperature under a nitrogen atmosphere. Stirred for 16 hours and then concentrated in vacuo.  
10 The residue was partitioned between water and dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give an oily solid. Trituration with hexanes gave 7.24 g of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid  
15 4-hydroxy-2,6-diisopropyl-phenyl ester as a white solid; mp 182-183°C.

Step (f) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester

Solid sodium hydride (0.16 g, 4 mmol) was added to a solution of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6-diisopropyl-phenyl ester (1.0 g, 1.9 mmol) in 50 mL of N,N-dimethylformamide.  
25 The resulting mixture was stirred for 1 hour before a mixture of triethylamine (1.08 mL, 7.8 mmol) and 3-dimethylaminopropylchloride hydrochloride (1.22 g, 3.9 mmol) in 75 mL tetrahydrofuran was added dropwise. The resulting mixture was stirred for 16 hours and then  
30 concentrated in vacuo. The residue was partitioned between saturated citric acid and dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give an oily solid. Trituration with a small amount of diethyl ether gave  
35 0.36 g of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic



-37-

acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester as a white foam.

## EXAMPLE 15

5     Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt

----- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl  
10     ester (0.2 g) was suspended in 50 mL of diethyl ether  
and HCl(g) was bubbled through the solution for  
15 minutes. The solution was concentrated in vacuo to  
give [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic  
acid-4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl  
15     ester hydrochloride salt as a white foam.

## EXAMPLE 16

20     Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt

Step (a) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butoxycarbonylamino-propoxy)-2,6-diisopropyl-phenyl ester

25     This compound was prepared in the same manner as  
Example 14, except that 3-tert-butoxycarbonylamino-propyl alcohol was used in place of the triethylamine and 3-dimethylaminopropylchloride hydrochloride mixture.

30     Step (b) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt

35     HCl(g) was bubbled through a solution of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butoxycarbonylamino-propoxy)-2,6-diisopropyl-phenyl ester in 150 mL methanol for 15 minutes. Concentrated

-38-

in vacuo and triturated the residue with 50% diethyl ether in hexanes to give [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt as an off-white solid.

## EXAMPLE 17

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester

Step (a) Sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester

N-Chlorosulfonyl isocyanate (1.02 mL, 11.7 mmol) was added to a warm solution of 2,6-diisopropyl-4-thiocyanato-phenol (2.5 g, 10.6 mmol) in 150 mL toluene. The resulting solution was heated to reflux for 6 hours and then cooled to room temperature and stirred overnight. The reaction was concentrated in vacuo and the residue was quenched with ice water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give 1.75 g of sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester as a white solid.

Step (b) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester

Oxalyl chloride (0.6 mL, 6.9 mmol) was added dropwise to a solution of 2,4,6-triisopropylphenyl acetic acid (1.52 g, 5.8 mmol) in 150 mL toluene with 4 drops of N,N-dimethylformamide as a catalyst. The resulting solution was stirred overnight and then concentrated in vacuo. The residue was redissolved in 150 mL dichloromethane. Sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester (1.70 g, 5.8 mmol) and

-39-

triethylamine (2.0 mL) were added, and the resulting mixture was stirred for 2 hours. Washed with 1M HCl, dried the organic layer over magnesium sulfate, filtered, and concentrated to give 2.24 g of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid  
5 2,6-diisopropyl-4-thiocyanato-phenyl ester as a white solid; mp 164-165°C.

---

## EXAMPLE 18

10 Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester  
Oxalyl chloride (0.48 mL, 5.5 mmol) was added dropwise to a solution of 2,4,6-triisopropylphenyl acetic acid (1.21 g, 4.6 mmol) in 100 mL toluene with  
15 4 drops of N,N-dimethylformamide as a catalyst. The resulting solution was stirred overnight and then concentrated in vacuo. The residue was re-dissolved in 150 mL dichloromethane. 2,6-Bis(1-methylethyl)-4-cyanophenyl sulfamate (1.30 g, 4.6 mmol) and  
20 triethylamine (1.6 mL) were added, and the resulting mixture was stirred for 6 hours. Washed with 1 M HCl, dried the organic layer over magnesium sulfate, filtered, and concentrated to give an oily solid. Chromatography on silica gel (20% ethyl acetate/  
25 hexanes) gave 1.11 g of the title compound as a white solid; mp 79-84°C.

## EXAMPLE 19

30 Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[(2-amino-acetylamino)-methyl]-2,6-diisopropyl-phenyl ester  
Step (a) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(aminomethylene)-2,6-diisopropyl-phenyl ester  
35 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester (5.15 g, 9.8 mmol)

-40-

was dissolved in 100 mL of methanolic ammonia and 2.0 g of Raney-nickel was added. The resulting mixture was stirred under 50 psi of hydrogen at room temperature for 20 hours. Filtered and concentrated the residue to give a dark solid. Suspended in diethyl ether and acidified with HCl gas. Concentrated in vacuo and neutralized the residue with saturated aqueous sodium bicarbonate. The resulting white suspension was used without further purification.

Step (b) [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[(2-amino-acetyl-amino)-methyl]-2,6-diisopropyl-phenyl ester

When in the procedure of Example 1, bis-N,N'-(t-butoxycarbonyl)-(S)-lysine is replaced with N-(9-fluorenylmethoxycarbonyl)-glycine, [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester is replaced by [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(aminomethylene)-2,6-diisopropyl-phenyl ester, and the crude product is stirred in 20% piperidine/N,N-dimethylformamide for 0.5 hours followed by trituration with hexanes, the title compound is obtained; mp 193-195°C.

#### EXAMPLE 20

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-2,6-diisopropyl-phenyl ester

When in the procedure of Example 8, 2,6-Bis(1-methylethyl)-4-cyanophenyl sulfamate is replaced with 2,6-bis(1-methylethyl)-4-formylphenyl sulfamate, the title compound is obtained; mp 71-76°C.

-41-

## EXAMPLE 21

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester

5 Diethylcyanomethyl phosphonate (1.49 mL, 9.2 mmol) was added dropwise to a suspension of sodium hydride (0.37 g, 9.2 mmol) in 20 mL tetrahydrofuran at 0°C. After 15 minutes, the reaction was cooled to -78°C and a solution of [(2,4,6-triisopropyl-phenyl)-acetyl]-  
10 sulfamic acid 4-formyl-2,6-diisopropyl-phenyl ester (2.32 g, 4.4 mmol) in 75 mL tetrahydrofuran was added dropwise. The reaction was allowed to warm to room temperature overnight and then concentrated in vacuo and partitioned the residue between 1 M HCl and  
15 dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give an oily solid. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 1.16 g of the title compound as a white solid; mp 157-160°C.

20

## EXAMPLE 22

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester mono hydrochloride

25 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-2,6-diisopropyl-phenyl ester (1.0 g, 1.9 mmol), benzylamine (0.21 mL, 1.9 mmol), and sodium triacetoxyborohydride (0.56 g, 2.6 mmol) were mixed in 100 mL of dichloromethane under a dry air atmosphere  
30 for 16 hours. Quenched by adding saturated sodium bicarbonate (50 mL). The resulting white solid was collected by filtration and resuspended in diethyl ether. HCl gas was bubbled through for 30 minutes, and the resulting solution was concentrated in vacuo to  
35 give the title compound as a white solid; mp 179-183°C.

-42-

## EXAMPLE 23

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester, dihydrochloride

5           When in the procedure of Example 22, benzylamine is replaced with 1-methyl piperazine, the title compound is obtained; mp 166-172°C.

## EXAMPLE 24

10       Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester

          3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-benzoic acid methyl ester (3.13 g, 5.6 mmol) was dissolved in a 3:1 methanol/1 M NaOH solution and stirred for 16 hours, concentrated in vacuo, and partitioned the residue between water and diethyl ether. The aqueous layer was acidified with concentrated HCl and extracted with ethyl acetate to give 2.85 g of the carboxylic acid as an off-white solid. Oxalyl chloride (0.16 mL, 1.8 mmol) was added dropwise to a suspension of the carboxylic acid (0.9 g, 1.65 mmol) in 50 mL toluene with 4 drops of N,N-dimethylformamide as a catalyst. The resulting solution was stirred for 2 hours, and then concentrated in vacuo. The residue was re-dissolved in 30 mL of methanolic ammonia, and the resulting mixture was stirred overnight. Concentrated in vacuo and partitioned between 1 M HCl and ethyl acetate. Dried the organic layer over magnesium sulfate, filtered, and concentrated to give a white solid. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 0.17 g of the title compound as a white foam.

-43-

## EXAMPLE 25

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester

5           3.9 mL of a 1 M solution of diisobutyl aluminum hydride in dichloromethane was added to a solution of 3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-benzoic acid methyl ester (1.0 g, 1.8 mmol) in 125 mL dichloromethane at -78°C. After  
10   3 hours, the reaction was warmed to room temperature and then quenched with a saturated aqueous sodium sulfate solution. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated to give a white foam. Triturated with 10%  
15   diethyl ether/hexanes to give 0.29 g of the title compound as a white solid; mp 163-168°C.

## EXAMPLE 26

20           Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetylamino-2,6-diisopropyl-phenyl ester

          [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester (1.0 g, 1.9 mmol) was mixed with 0.54 mL (3.8 mmol) of triethyl amine in  
25   50 mL of tetrahydrofuran at room temperature. Acetyl chloride (0.14 mL, 1.9 mmol) was added, and the resulting suspension was stirred overnight. Concentrated in vacuo and partitioned the oily residue between 1 M HCl and dichloromethane. Dried the organic  
30   layer over magnesium sulfate, filtered, and concentrated to give an orange foam. Chromatography on silica gel (20% ethyl acetate/hexanes) gave 0.56 g of the title compound as a white solid; mp 203-205°C.

-44-

## EXAMPLE 27

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-hydroxy-ethylamino)-2,6-diisopropyl-phenyl ester

5            [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid  
4-amino-2,6-diisopropyl-phenyl ester (1.0 g, 1.9 mmol)  
was suspended in 50 mL of 1:1 glacial acetic acid/water  
and a stream of ethylene oxide was bubbled in for  
15 minutes. The reaction mixture was sealed and  
10            allowed to stir overnight. The reaction mixture was  
concentrated in vacuo and partitioned between saturated  
aqueous sodium bicarbonate and dichloromethane. Dried  
the organic layer over magnesium sulfate, filtered, and  
concentrated to give an oily solid. Chromatography on  
15            silica gel (20% ethyl acetate/hexanes) gave 0.07 g of  
the title compound as a tan solid; mp 149-152°C.

## EXAMPLE 28

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-ethyl)-amino]-2,6-diisopropyl-phenyl ester

20            When in the procedure of Example 27, glacial  
acetic acid is used instead of a glacial acetic  
acid/water mixture and it is heated to 50°C in a sealed  
25            tube for 15 hours, the title compound is obtained;  
mp 143-146°C.

## EXAMPLE 29

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester

30            When in the procedure of Example 7, ethyl  
3-isocyanatopropionate is replaced with  
2,6-diisopropylphenyl isocyanate, the title compound is  
35            obtained; mp 133-135°C.



-45-

## EXAMPLE 30

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureidol)-  
phenyl ester

- 5           When in the procedure of Example 7, ethyl  
3-isocyanatopropionate is replaced with phenyl  
isocyanate, the title compound is obtained;  
mp 185-187°C.

## EXAMPLE 31

- 10           Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 2,6-diisopropyl-4-(3-phenyl-thioureidol)-  
phenyl ester

- 15           When in the procedure of Example 7, ethyl  
3-isocyanatopropionate is replaced with phenyl  
isothiocyanate, the title compound is obtained;  
mp 173-175°C.

## EXAMPLE 32

- 20           Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 2,6-diisopropyl-4-(thiophene-2-  
sulfonylamino)-phenyl ester

- 25           When in the procedure of Example 26, acetyl  
chloride is replaced with thiophene-2-yl sulfonyl  
chloride, the title compound is obtained.

## EXAMPLE 33

- 30           Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 4-(5-dimethylamino-naphthalene-1-  
sulfonylamino)-2,6-diisopropyl-phenyl ester

When in the procedure of Example 26, acetyl  
chloride is replaced with dansyl chloride, the title  
compound is obtained; mp 103-105°C.

-46-

## EXAMPLE 34

Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6 diisopropyl-4methanesulfonylamino-phenyl ester

5           When in the procedure of Example 26, acetyl chloride is replaced with methanesulfonyl chloride, the title compound is obtained; mp 164-166°C.

## EXAMPLE 35

10       Synthesis of [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6 diisopropyl-4-sulfonyl-phenyl ester

          Sodium nitrite (0.78 g, 11.3 mmol) in 1.25 mL H<sub>2</sub>O was added to a solution of [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6 diisopropyl-phenyl ester (3.875 g, 7.5 mmol) in 10 mL AcOH and 1.75 mL concentrated HCl. The diazotized solution was stirred for 1/2 hour before pouring into a saturated solution of SO<sub>2</sub> containing 0.25 g of CuCl<sub>2</sub> in 20 mL AcOH and 20 mL benzene. After stirring overnight, the solution was poured onto ice water and precipitated [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-sulfonyl chloride-phenyl ester which was collected by filtration, total weight 3.8 g, (84%). Ammonia gas was bubbled through a solution of [(2,4,6-triisopropyl phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-sulfonyl chloride-phenyl ester (1 g, 1.7 mmol) in 10 mL THF. The precipitate was collected and purified by column chromatography (1:1 = EtOAc/Hexane), white powder obtained weight 0.5 g; mp 164-166°C.

-47-

## EXAMPLE 36

Synthesis of 6-(3,5-Diisopropyl-4-[[2,4,6-triisopropyl-phenyl-acetyl]sulfamoyloxy]-phenyl)-hexanoic acid ethyl ester

5        When in the procedure of Example 18, 2,6-bis(1-methylethyl)-4-cyanophenyl sulfamate is replaced with 6-(3,5-Diisopropyl-4-sulfamoyloxy-phenyl)-hexanoic acid ethyl ester, the title compound is obtained as a white solid from hexanes, 0.1441 g.

10       Atmospheric pressure CI Mass Spectrum:  $[M + H]^+ = 644.4$ .

## EXAMPLE 37

15       Synthesis of 6-(3,5-Diisopropyl-4-[[2,4,6-triisopropyl-phenyl-acetyl]sulfamoyloxy]-phenyl)-hexanoic acid

6-(3,5-Diisopropyl-4-[[2,4,6-triisopropyl-phenyl-acetyl]sulfamoyloxy]-phenyl)-hexanoic acid ethyl ester (1.52 g, 2.36 mmol) is taken up in methanol (20 mL) and 20       1N sodium hydroxide solution is added, and the mixture is stirred at room temperature. Water is added to the reaction mixture as the reaction proceeds. The reaction mixture is stirred overnight at room temperature and then concentrated to remove methanol. The resulting 25       mixture is partitioned between ethyl acetate and citric acid solution (10% aqueous, 100 mL). The layers are separated, the organic layer is washed with brine, dried over magnesium sulfate, filtered, and concentrated to an oil. The oil is chromatographed on silica gel 30       (70-230 mesh) using hexanes/ethyl acetate, 1:1, v/v. The product is obtained as a white solid from hexanes, 0.992 g.


Atmospheric pressure CI Mass Spectrum:  $[M - H] = 614.4$ .

-48-

## CLAIMS

We claim:

1. A compound of formula



or a pharmaceutically acceptable salt thereof

10 wherein:

 $R^1$  is hydrogen, alkyl, or alkoxy; $R^2$  to  $R^5$  are alkyl, alkoxy, or unsubstituted or substituted phenyl; $R^6$  is -CN,15  $-(CH_2)_{0-1}-NR^7R^8$ , $-O-(CH_2)_{1-10}-Z$  wherein Z is  $-NR^9R^{10}$ ,  $OR^1$ , or  $CO_2R^1$ , $-OC(=O)R^{11}$ , $-SR^{11}$ ,20  $-SCN$ , $-S(CH_2)_{1-10}Z$ , $-S(O)_{1-2}R^{12}$  wherein  $R^{12}$  is hydroxy, alkoxy, alkyl,  $(CH_2)_{1-10}Z$  or  $NR^7R^8$ , $-C(=O)XR^{11}$ ,25  $-CH_2-R^{13}$  wherein  $R^{13}$  is  $(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$ ,  
or

alkyl of from 1 to 20 carbons with from

1-3 double bonds, which alkyl is

optionally substituted by one or more

30 selected from -CN,  $NO_2$ , halogen,  $OR^1$ ,  $NR^9R^{10}$ , and  $CO_2R^1$ ;wherein  $R^7$  and  $R^8$  are each independently selected from:

-49-

- 35 -hydrogen, at least one of  $R^7$  and  $R^8$  is other than hydrogen,
- $(CH_2)_{1-10}Z$  wherein  $Z$  is as above and  $R^9$  and  $R^{10}$  are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl, or
- 40  $R^9$  and  $R^{10}$  are taken together with the nitrogen to which they are attached to form a ring selected from:
- $(CH_2)_2-O-(CH_2)_2$ ,
  - $(CH_2)_2-S-(CH_2)_2$ ,
  - 45 -  $(CH_2)_2-CR^{14}R^{15}-(CH_2)_{1-2}$ , and
  - $(CH_2)_2-NR^{16}-(CH_2)_2$ , wherein  $R^{14}$ ,  $R^{15}$ , and  $R^{16}$  are each independently selected from hydrogen, alkyl, and
  - 50 unsubstituted or substituted phenyl;
- $C(=Q)XR^{11}$  wherein  $X$  is a bond or  $NH$  wherein  $Q$  is  $O$  or  $S$ ,  $R^{11}$  is hydrogen, alkyl, unsubstituted or
- 55 substituted phenyl,
- $(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$  wherein  $Z$  is as defined above and  $Y$  is phenyl or a bond;
- $C(=O)CR^{17}R^{18}Z$ ;
- 60 -  $C(=O)NRCR^{17}R^{18}Z$  wherein  $R^{17}$  and  $R^{18}$  are each independently hydrogen, alkyl, phenyl, substituted phenyl, or the side chain of a naturally occurring amino acid;
- $S(O)_{1-2}R^{19}$  wherein  $R^{19}$  is alkyl,
- 65 unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring, or  $NR^9R^{10}$  or

-50-

70  $R^7$  and  $R^8$  are taken together with the  
nitrogen to which they are attached to form a  
ring:

75  $-(CH_2)_2-O-(CH_2)_2-$ ,  
 $-(CH_2)_2-S-(CH_2)_2-$ ,  
 $-(CH_2)_2-CR^{14}R^{15}-(CH_2)_1-2-$ ,  
 $-(CH_2)_2-NR^{16}-(CH_2)_2-$  wherein  $R^{14}$ ,  $R^{15}$ ,  
and  $R^{16}$  are as above.

2. A compound according to Claim 1 wherein:  
 $R^1$  is hydrogen or alkyl of from 1 to 4 carbon  
atoms;  
 $R^2$  to  $R^5$  are each alkyl of from 1 to 4 carbon  
atoms;  
5  $R^6$  is  $-NR^7R^8$  wherein  $R^7$  and  $R^8$  are each  
independently selected from:  
hydrogen, at least one of  $R^7$  and  $R^8$  is  
not hydrogen,  
10  $-(CH_2)_{1-10}Z$ ,  
 $-C(=Q)XR^{11}$ , or  
 $-S(O)_{1-2}R^{19}$ .
3. A compound according to Claim 2 wherein:  
 $R^7$  is hydrogen and  
 $R^8$  is  $-C(=O)CR^{17}R^{18}Z$  wherein  $Z$  is  $NH_2$ , wherein one  
of  $R^{17}$  or  $R^{18}$  is the side chain of a  
5 naturally occurring amino acid and the other  
is hydrogen.
4. A compound according to Claim 2 wherein:  
 $R^1$  is hydrogen or alkyl of from 1 to 4 carbon  
atoms;  
 $R^2$  to  $R^5$  are each alkyl of from 1 to 4; carbon  
atoms  
5  $R^6$  is  $NR^7R^8$  wherein one of  $R^7$  is hydrogen and the  
 $R^8$  is  $S(O)_{1-2}R^{19}$ .

-51-

5. A compound according to Claim 1 wherein:

$R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;

$R^2$  to  $R^5$  are each alkyl of from 1 to 4 carbon atoms;

$R^6$  is  $NR^7R^8$  wherein  $R^7$  and  $R^8$  taken together with the nitrogen to which they are attached to form a ring:

-  $(CH_2)_2-O-(CH_2)_2-$ ,

-  $(CH_2)_2-S-(CH_2)_2-$ ,

-  $(CH_2)_2-CR^{14}R^{15}-(CH_2)_2-$  wherein  $R^{14}$  and  $R^{15}$  are each independently selected

from hydrogen, alkyl, or phenyl, or

-  $(CH_2)_2-NR^{16}-(CH_2)_2-$  wherein  $R^{16}$  is hydrogen, alkyl, or phenyl.

6. A compound according to Claim 1 wherein:

$R^1$  is hydrogen or alkyl of from 1 to 4 carbons,

$R^2$  to  $R^5$  an alkyl of from 1 to 4 carbons, and

$R^6$  is  $-C(=O)XR^{11}$  or  $-CH_2-R^{13}$ .

7. A compound according to Claim 1 wherein:

$R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;

$R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms;

$R^6$  is  $-O-(CH_2)_{1-10}Z$ ,

$-O-C(=O)R^{11}$ ,

$-SH$ ,

$-SCN$ ,

$-S(CH_2)_{1-10}Z$ , or

$-S(O)_{1-2}R^{12}$ .

-52-

8. A compound according to Claim 6 wherein:  
 $R^1$  is hydrogen or alkyl of from 1 to 4 carbon atoms;  
 $R^2$  to  $R^5$  are alkyl of from 1 to 4 carbon atoms;  
 $R^6$  is  $O(CH_2)_{1-10}NR^9R^{10}$ .
9. A compound according to Claim 1 and selected from:
- (S)-[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester;
- (S)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2,6-diamino-hexanoylamino)-2,6-diisopropyl-phenyl ester dihydrochloride;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-acetylamino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetylamino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butrylamino)-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-4-methylsulfanyl-butrylamino)-2,6-diisopropyl-phenyl ester trifluoroacetate;
- 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenyl)-ureido]-propionic acid ethyl ester;
- 3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenyl)-ureido]-propionic acid;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionylamino]-2,6-diisopropyl-phenyl ester;



-53-

- 30 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(5-amino-pentanoylamino)-2,6-diisopropyl-  
phenyl ester trifluoroacetate(1:1) (salt);  
(D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 4-(2-amino-propionylamino)-2,6-  
35 diisopropyl-phenyl ester trifluoroacetate(1:1)  
(salt);
- 
- (L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-  
sulfamic acid 4-(2-amino-propionylamino)-2,6-  
diisopropyl-phenyl ester;
- 40 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(2-amino-2-methyl-propionylamino)-2,6-  
diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-  
45 phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-  
phenyl ester hydrochloride salt;
- 50 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl  
ester hydrochloride salt;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 2,6-diisopropyl-4-thiocyanato-phenyl ester;
- 55 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-cyano-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-[(2-amino-acetylamino)-methyl]-2,6-  
diisopropyl-phenyl ester; -
- 60 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-formyl-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl  
ester;

-54-

- 65 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester mono hydrochloride;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester, dihydrochloride;
- 70 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester;
- 75 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetyl-amino-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-hydroxy-ethylamino)-2,6-diisopropyl-phenyl ester;
- 80 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-ethyl)-amino]-2,6-diisopropyl-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester;
- 85 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-thioureido)-phenyl ester;
- 90 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(thiophene-2-sulfonyl-amino)-phenyl ester;
- [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-dimethylamino-naphthalene-1-sulfonylamino)-2,6-diisopropyl-phenyl ester;
- 95 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester;

-55-

100 [(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic  
acid 2,6-diisopropyl-4-sulfamoyl-phenyl ester;  
6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-  
phenyl-acetyl)sulfamoyloxy]-phenyl)-hexanoic acid  
ethyl ester; and  
105 6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-  
phenyl-acetyl)sulfamoyloxy]-phenyl)-hexanoic acid.

---

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
11. A method of treating hypercholesterolemia comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound of Claim 1.
12. A method of treating atherosclerosis comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound of Claim 1.
13. A method of regulating plasma cholesterol concentrations comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound according to Claim 1.  
5
14. A method for lowering the serum or plasma level of Lp(a) in a mammal in need of said treatment, comprising administering to said mammal an amount effective for lowering the serum or plasma level of said Lp(a) of a compound according to Claim 1.  
5

-56-

15. A method of treating peripheral vascular disease comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound according to Claim 1.
16. A method of treating restenosis comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound according to Claim 1.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 97/06725

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07C307/02 A61K31/225 C07D209/20 C07C331/10 C07D295/08  
C07D333/34 C07C323/59

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07C A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 491 172 A (LEE H T ET AL) 13 February 1996 see column 4, line 23 - line 39 see claims -----	1-16

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

16 September 1997

Date of mailing of the international search report

23.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Pauwels, G

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/06725

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 11-16  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/06725

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5491172 A	13-02-96	AU 681152 B	21-08-97
		AU 6831194 A	12-12-94
		CA 2158268 A	24-11-94
		CZ 9502966 A	11-09-96
		EP 0698010 A	28-02-96
		FI 955438 A	10-11-95
		HU 72653 A	28-05-96
		JP 8510256 T	29-10-96
		NO 954564 A	11-01-96
		SK 139695 A	06-11-96
		WO 9426702 A	24-11-94
		US 5633287 A	27-05-97
		ZA 9403313 A	13-11-95

**THIS PAGE BLANK (USPTO)**